Breaking Finance News

Raymond James disclosed PRA Health Sciences (NASDAQ:PRAH), boosting its price target to $89.00 earlier today

Yesterday PRA Health Sciences (NASDAQ:PRAH) traded 0.64% higher at $75.16. The company’s 50-day moving average is $75.23 and its 200-day moving average is $67.76. The last stock close price is up 11.63% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 100,115 shares of the stock were exchanged, down from an average trading volume of 552,717

Reporting a potential upside of 0.18%, Raymond James upped the price target of PRA Health Sciences (NASDAQ:PRAH) to $89.00

Previously on Monday June 26, 2017, BofA Merrill reported about PRA Health Sciences (NASDAQ:PRAH) raised the target price from $0.00 to $89.00. At the time, this indicated a possible upside of 0.18%.

See Chart Below

PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences has a 52 week low of $48.42 and a 52 week high of $80.99 with a P/E ratio of 48.83 The company’s market cap is currently $0.

In addition to Raymond James reporting its target price, a total of 7 firms have issued a report on the stock. The consensus target price is $52.79 with 5 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 1 firm rating the stock a sell.

General Information About PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.